申请人:YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.
公开号:EP0602242A1
公开(公告)日:1994-06-22
A benzisoxazole compound represented by general formula (I) or a pharmaceutically acceptable salt thereof wherein, when the bond (a) between the 2- and 3-positions represents a single bond, Ra represents the group (II) (wherein R represents hydrogen, alkyl, alkenyl, cycloalkylalkyl, cycloalkylalkenyl, phenylalkenyl, naphthylalkyl or naphthylalkenyl; A represents linear or branched alkylene; and n represents 1, 2 or 3) and Rb represents oxygen, or alternatively when the bond (a) between the 2- and 3-positions represents a double bond, Ra is absent; Rb represents either the group (III), wherein each symbol is as defined above, or the group (IV), wherein E represents oxygen or sulfur, and R, A and n are each as defined above; and R¹, R², R³ and R⁴ are each as defined in the specification. This compound has a centroselective acetylcholine esterase inhibiting activity and/or a potent affinity for sigma receptor.
通式(I)代表的苯并异噁唑化合物或其药学上可接受的盐 其中,当 2-位和 3-位之间的键(a)代表单键时,Ra 代表基团(II)(其中 R 代表氢、烷基、烯基、环烷基、环烷烯基、苯基烯基、萘基或萘基烷基;A 代表直链或支链亚烷基;和 n 代表 1、2 或 3),Rb 代表氧,或者当 2 位和 3 位之间的键 (a) 代表双键时,Ra 不存在;Rb 代表基团 (III)(其中每个符号如上文所定义)或基团 (IV)(其中 E 代表氧或硫),R、A 和 n 均如上文所定义;R¹、R²、R³ 和 R⁴ 均如说明书中所定义。该化合物具有中心选择性乙酰胆碱酯酶抑制活性和/或对 sigma 受体的强亲和力。